GNCA stock hits $0.0001 intraday Jan 30, 2026 NASDAQ: Watch cash runway
GNCA stock plunged 97.44% intraday to USD 0.0001 on Jan 30, 2026 on the NASDAQ, ranking it among today’s top losers. Trading volume reached 30,268 shares versus a 50-day average of 80,568, signalling limited liquidity. The tumble follows multi-year operational distress and a prior Chapter 11 reorganization notice, leaving market participants focused on cash, potential delisting risk, and near-term catalysts for any recovery.
GNCA stock intraday price action and drivers
Today GNCA stock moved to USD 0.0001 from a previous close of USD 0.0039, a -97.44% change. The stock opened at USD 0.0007 and traded in a very tight band at the low. Volume was 30,268.00 versus an average volume of 80,568.00, showing muted participation. Recent corporate events include the Chapter 11 filing disclosure in 2022 and continued clinical-stage uncertainty for GEN-009 and GEN-011, which appear to weigh on valuation and liquidity. For direct company detail see the Genocea site: company site.
GNCA stock fundamentals and key metrics
Genocea Biosciences, Inc. operates in Healthcare, specifically Biotechnology. Key balance-sheet metrics show cash per share USD 0.5417, book value per share USD 0.3948, and current ratio 2.24, which supports short-term obligations. Trailing metrics show negative operating cash flow per share USD -0.66 and free cash flow per share USD -0.71. Revenue per share is USD 0.02, while net income per share is USD -0.22. Market cap is reported at USD 0.00, reflecting extremely thin market value and possible reporting limitations.
GNCA stock trading signals and technical context
Short-term averages are depressed: 50-day price average is USD 0.0047 and 200-day average USD 0.1146. The large gap to moving averages signals prolonged sell pressure and potential delisting risk if volume and price remain near zero. Liquidity is low: relative volume is 0.38. Technical support is effectively at the current low of USD 0.0001; any bounce would face resistance near the 50-day average. Traders should expect outsized volatility and wide bid-ask spreads.
Meyka AI rates GNCA with a score out of 100 and analysis
Meyka AI rates GNCA with a score out of 100: Score 58.64 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, industry metrics, financial growth, key ratios, forecasts, and analyst consensus. The grade reflects a weak market valuation but some balance-sheet cushions like cash per share and current ratio. This grade is informational only and not investment advice.
GNCA stock price targets, risks, and scenario outlook
Scenario-based targets: Bear case USD 0.00 (delisting/liquidation outcome), Base case USD 0.0001 (status quo trading), Bull case USD 0.01 (low-probability recovery tied to asset sale or funding). Key risks include continued clinical setbacks, thin liquidity, and potential NASDAQ compliance action. Opportunities would require new financing, asset realizations, or meaningful clinical readouts. No consensus analyst price target is available publicly.
Final Thoughts
GNCA stock’s intraday drop to USD 0.0001 on Jan 30, 2026 highlights deep distress in this small-cap biotech on the NASDAQ. Balance-sheet metrics show cash per share USD 0.54 and a current ratio 2.24, which provide a short runway cushion, but operating cash flow remains negative at USD -0.66 per share. Meyka AI’s forecast model projects USD 0.00 over the horizon, compared to the current price of USD 0.0001, implying an effective downside scenario of about -100% if liquidation or delisting occurs. Meyka AI’s grade of 58.64 (C+, HOLD) reflects mixed factors: fragile market value but non-zero tangible book value. For investors, GNCA stock should be treated as a high-risk speculative situation driven by liquidity, legal and clinical outcomes. Monitor cash disclosures, any SEC or exchange notices, and potential financing events. Forecasts are model-based projections and not guarantees; position sizing and risk limits are essential for exposure to GNCA stock.
FAQs
Why did GNCA stock fall so sharply today?
GNCA stock fell to USD 0.0001 amid limited liquidity and persistent operational uncertainty. Trading volume was low relative to averages and market concern about capital sufficiency and past Chapter 11 disclosures likely amplified sell pressure.
What is Meyka AI’s view on GNCA stock valuation?
Meyka AI assigns GNCA a 58.64 score (C+, HOLD). The valuation reflects zero market cap reporting, some cash per share, and negative operating cash flows, suggesting high downside risk without new financing or asset sales.
Does GNCA stock have a forecast or price target?
Meyka AI’s forecast model projects USD 0.00 versus the current USD 0.0001, implying substantial downside in a liquidation scenario. Scenario targets include a bull case at USD 0.01, but that remains low probability without major events.
How should traders approach GNCA stock trading today?
Treat GNCA stock as highly speculative and illiquid. Use tight position sizing, expect wide spreads, and monitor filings or NASDAQ notices. Focus on cash runway disclosures and funding announcements before increasing exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
